Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167761 · ClinicalTrials.gov registry record · Early Phase 1
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 61
- Enrollment target
NCT04167761: Completed Early Phase 1 study, sponsored by Stanford University.
NCT04167761 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04167761, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Interventions
- DRUG Ertugliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2023-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04167761
The ClinicalTrials.gov registry entry for NCT04167761 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ertugliflozin is the first listed.
NCT04167761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04167761 about?
NCT04167761 is a clinical study titled "Ertugliflozin: Cardioprotective Effects on Epicardial Fat". The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
What is the current status of trial NCT04167761?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 61 participants. The study started on 2020-07-01. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT04167761?
The interventions under investigation include: Ertugliflozin (DRUG).
Who is sponsoring clinical trial NCT04167761?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.